Home Companies Catalysts Deep Dives
Entresto sacubitril/valsartan APPROVED
Drug Profile
ModalitySmall molecule
RouteOral
Therapy AreaCVRM
Launch2015-07-07
US LOE2025-07-07
Peak Sales Est$7000M
Formulations[{"id":"entresto-oral","doses":"24/26mg, 49/51mg, 97/103mg tablets","route":"Oral","setting":"PATIEN
Companies
NVS (ORIGINATOR)100%
Mechanism: ARNI (Angiotensin receptor-neprilysin inhibitor)
Expert: Dual inhibition of angiotensin II receptor and neprilysin, reducing neurohormonal overactivation in heart failure
Everyday: Blocks harmful hormones while preserving beneficial ones to reduce strain on the heart
Targets: ["AT1","NEP"]
Revenue History
PeriodRevenue ($M)
2024$7,820M
2025$7,100M
Q4 2024$1,950M
Q4 2025$1,650M
Programs (2)
IndicationStageKey StudyRegional Status
HFrEFAPPROVEDPARADIGM-HF[{"stage":"APPROVED","region":"US","approval_date":"2015-07"}]
HFpEFAPPROVEDPARAGON-HF[{"stage":"APPROVED","region":"US","approval_date":"2021-02"}]
Upcoming Catalysts (1)
Entresto - Generic Competition Impact 2026
Notes
ARNI for heart failure. Blockbuster facing 2025 LOE. Key growth driver through 2025.
Data from Supabase · Updated 2026-03-24